Home » Newsletters » BioWorld Science

BioWorld Science

May 25, 2020

View Archived Issues

Optimized benzoxazolone carboxamides for oral treatment of neurological lysosomal storage diseases

SIRPa blockade wakes up macrophages after infection

Lasting immunity to SARS-CoV-2 looks possible

RDIF and ChemRar launch final stage of favipiravir study in patients with COVID-19

Positive data from outpatient portion of a phase II study of RTU glucagon

Daiichi Sankyo presents new 5-HT2A receptor agonists

FDA accepts IND application for phase I/II study of NT-219 in advanced cancer

Beijing Tide Pharmaceutical patents ROCK2 inhibitors

Chinese investigators divulge coagulation factor XIa inhibitors

Roche synthesizes new TLR antagonists

Fidget spinner allows point-of-care diagnosis of UTIs

GlaxoSmithKline plc synthesizes new H-PGDS inhibitors

Phase I/II data presented for LY-500307 in men with schizophrenia

Serum KL-6 as a biomarker for the management of Mycobacterium avium complex lung disease

HCP5 is a diagnostic and prognostic marker in AML

Phase III trial of Dupixent for eosinophilic esophagitis meets coprimary endpoints

FDA approves Alunbrig for ALK-positive metastatic NSCLC

FDA approves Phexxi gel to prevent pregnancy

Phase I/II trial evaluates LS-301 uptake in breast cancer patients

A new oxime that crosses the blood-brain barrier as a treatment for organo-phosphate poisoning

Identification of a new peptide targeting the HR1 spike domain as a pan-coronavirus fusion inhibitor

Kynomycin, a methylated daptomycin analogue, shows promise for multidrug-resistant pathogens

First clinical data presented for PfSPZ-GA1 antimalarial vaccine

A human monoclonal antibody neutralizing SARS-CoV-2 and SARS-CoV infections

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...